In this article, we will be taking a look at the 5 Popular Penny Stocks on Robinhood to Watch in 2026. If you wish to see the full list, visit 10 Popular Penny Stocks on Robinhood to Watch in 2026.
5. Expensify, Inc. (NASDAQ:EXFY)
Stock Price as of Last Close of May 26: $1.15
Expensify, Inc. (NASDAQ:EXFY) is one of the most popular penny stocks.
TheFly reported on May 21 that EXFY announced a new integration with VAT IT, a global provider of VAT reclaim services, expanding its expense management ecosystem. The partnership allows users to automatically sync qualifying expense data with VAT IT to improve VAT recovery efficiency and reduce manual processing. The integration is designed to enhance international expense handling, particularly in regions such as Europe and Canada, where tax reclaim processes are widely used. It also enables centralized documentation, improved visibility into recoverable taxes, and smoother cross-border compliance workflows. The collaboration further strengthens Expensify’s platform by embedding additional indirect tax and e-invoicing capabilities into its existing expense, travel, and corporate card system.
Separately, on May 19, Expensify, Inc. (NASDAQ:EXFY) announced a strategic collaboration with Playroll aimed at improving global expense-to-payroll workflows for distributed teams. The integration links Expensify’s expense management system with Playroll’s payroll infrastructure, enabling approved expenses to move directly into payroll processing across more than 180 countries.
Expenses are converted into local currency, processed within the next payroll cycle, and continuously reconciled with payroll records to ensure accuracy and compliance. The solution is designed to eliminate reimbursement delays and reduce manual coordination between finance and HR teams. By connecting expense approvals directly to payroll execution, the partnership enhances visibility, streamlines cross-border payments, and supports automated compliance within international workforce operations.
Expensify, Inc. (NASDAQ:EXFY) is a cloud-based financial management platform that automates expense tracking and related business tasks, including receipts, invoicing, bill payments, and travel booking in one application.
4. GoPro, Inc. (NASDAQ:GPRO)
Stock Price as of Last Close of May 26: $1.20
GoPro, Inc. (NASDAQ:GPRO) is one of the most popular penny stocks.
TheFly reported on May 26 that GPRO and Dive with Buddy introduced GoPro Escapes, a new travel initiative focused on curated diving experiences led by creators and professionals. The program offers multi-day group trips designed for small gatherings of approximately 10 to 40 participants. These expeditions are hosted by GPRO athletes, underwater content creators, and certified dive instructors in selected global locations known for strong marine environments and visibility conditions. Each package includes lodging, guided diving activities, educational workshops, and branded experiential elements tied to GPRO’s ecosystem. The trips are available for booking through Buddy’s online platform and mobile application, expanding access to structured, experience-driven underwater adventure travel.
Separately, GoPro, Inc. (NASDAQ:GPRO) reported its first quarter 2026 financial results on May 11, covering the period ended March 31, 2026. The company recorded revenue of $99 million, reflecting a 26% decline year over year, alongside lower camera unit sell-through of 313,000 units. Subscription revenue remained stable at $27 million, though total subscriber numbers declined to 2.26 million. Retail and direct sales both decreased, with retail representing the larger share of total revenue. Gross margins fell sharply compared to the prior year due to inventory-related charges and component cost adjustments. Net loss widened to $81 million, while adjusted EBITDA remained negative. The company also highlighted a new product launch in May, introducing the MISSION 1 Series, marking its entry into the high-end cinema camera segment.
GoPro, Inc. (NASDAQ:GPRO) is a technology company known for pioneering action cameras, producing rugged high-definition cameras along with accessories and a subscription service for cloud storage and video editing.
3. Quince Therapeutics, Inc. (NASDAQ:QNCX)
Stock Price as of Last Close of May 26: $1.20
Quine Therapeutics, Inc. (NASDAQ:QNCX) is among the most popular penny stocks.
TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society conference in Orlando, evaluating an inhaled rapamycin formulation for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The drug was studied as an add-on to standard therapy in a 24-week, open-label trial across four sites involving 10 symptomatic adult patients. Outcomes assessed included exercise capacity, pulmonary hemodynamics, cardiac biomarkers, and safety measures.
Results showed improvements or stabilization across multiple disease indicators such as six-minute walk distance, pulmonary vascular resistance, NT-proBNP levels, and lung function metrics. Most patients improved functional class status over the study period, and the treatment was generally well tolerated alongside background therapies, including treprostinil in PH-ILD patients.
Simultaneously, on the same day, Quine Therapeutics, Inc. (NASDAQ:QNCX) announced the completion of its acquisition of Orphai Therapeutics Inc. on May 18, 2026, integrating Orphai’s lead candidate LAM-001 into its pipeline for rare pulmonary diseases. LAM-001, an inhaled rapamycin formulation, has recently shown Phase 2 clinical results in pulmonary arterial hypertension and PH-ILD. Alongside the acquisition, the company entered a financing arrangement expected to raise to $187 million in gross proceeds, including initial and potential additional warrant-based funding.
The capital is intended to support the advancement of LAM-001 through multiple upcoming clinical milestones across pulmonary indications, including PH-ILD, BOS, and sarcoidosis-associated pulmonary hypertension. Management highlighted that the transaction strengthens both the company’s pipeline and financial position.
Quine Therapeutics, Inc. (NASDAQ:QNCX) is a biotech company developing rare disease therapies using patients’ own biology. In May 2026, it expanded its pipeline by acquiring Orphai Therapeutics, adding programs in rare pulmonary and cardiovascular diseases.
2. PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)
Stock Price as of Last Close of May 26: $1.23
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is among the most popular penny stocks on Robinhood.
TheFly reported on May 13 that Oppenheimer reduced its price target on PMVP from $6 to $5 while maintaining an Outperform rating after the company’s latest quarterly update. The firm noted ongoing encouraging clinical activity for rezatapopt in ovarian cancer patients with the Y220C p53 mutation and KRAS wild-type tumors. Financial positioning showed $93.5 million in cash at the end of Q1, which is considered sufficient to support operations through the planned NDA submission in Q1 2027. However, additional funding would likely be required to sustain operations through the expected mid-to-late 2027 approval timeline for rezatapopt.
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) reported its first-quarter 2026 financial results on May 12, alongside a corporate update for the period ended March 31, 2026. The company highlighted continued enrollment progress in its Phase 2 PYNNACLE monotherapy study evaluating rezatapopt for TP53 Y220C-mutated advanced solid tumors, with regulatory submission plans for a New Drug Application targeted for Q1 2027. Clinical data presented earlier in the year showed meaningful response rates and sustained duration of benefit in ovarian cancer patients.
Financially, PMVP ended the quarter with $93.5 million in cash, down from $112.9 million previously, and reported higher net cash usage from operations alongside reduced R&D and G&A expenses. The update also included regulatory milestones such as an FDA orphan drug designation for rezatapopt across multiple rare ovarian-related cancers.
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) is a clinical-stage oncology company developing small-molecule therapies that aim to restore the function of the p53 tumor-suppressor protein to help treat cancer.
1. Cognition Therapeutics, Inc. (NASDAQ:CGTX)
Stock Price as of Last Close of May 26: $1.24
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is one of the most popular penny stocks on Robinhood.
TheFly reported on May 21 that CGTX held a planned regulatory meeting with the U.S. Food and Drug Administration to review Phase 2 results for zervimesine and discuss the framework for a future registrational study in dementia with Lewy bodies accompanied by psychosis. The discussion focused on clinical outcomes from the COG1201 “SHIMMER” trial and potential endpoints for advancing the program into later-stage development. Management described the meeting as productive and indicated that both parties reviewed the proposed path toward a registrational pathway for zervimesine in DLB-related psychosis. The company expects to receive formal meeting minutes in June, which will further clarify regulatory guidance and next steps for advancing the therapeutic program into pivotal-stage planning and continued clinical development activities.
Separately, Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its first-quarter 2026 financial results on May 7, 2026, covering the period ended March 31, 2026. The company reported a net loss of $4.6 million, or $0.05 per share, compared with $8.5 million, or $0.14 per share, in the prior year period. Operating costs declined year over year, with research and development expenses falling to $6.1 million from $10.8 million due to reduced clinical trial activity and lower external research spending. General and administrative expenses also decreased to $2.7 million from $3.0 million, driven by lower compensation and stock-based costs. As of March 31, 2026, Cognition held approximately $31.2 million in cash and equivalents, along with $25.6 million in remaining grant funding, supporting projected operations into the second quarter of 2027.
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a clinical-stage biotech company developing oral small-molecule therapies aimed at protecting neuronal synapses to slow or stop neurodegenerative and retinal diseases.
While we acknowledge the potential of CGTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CGTX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Best Reddit Stocks to Buy According to Billionaires and 10 Safe Stocks to Buy for the Long Term in 2026
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
